The loss of muscle mass and function in sarcopenia is associated with impaired physical function, reduced quality of life, and an increased risk of falls, illness, and death
Diabetes Vasc Dis Res (2011) 8(2):11724
tirzepatide combines GLP-1 with GIP activity
At 186 pounds and tired of feeling stuck, I decided to give this peptide a try after reading about the clinical trial results

Absorption rates can vary slightly depending on: Injection site Abdominal injections may be absorbed slightly faster than thigh injections Injection depth Proper subcutaneous technique ensures consistent absorption Site rotation Regular rotation prevents lipohypertrophy (fatty lumps) that can affect absorption Renal and Hepatic Function The impact of kidney and liver function varies by medication: Exenatide is contraindicated if your kidney function is severely reduced (eGFR/CrCl below 30 mL/min) Lixisenatide is not recommended in severe renal impairment (eGFR below 15 mL/min) Semaglutide, dulaglutide, and liraglutide generally don't require dose adjustment for mild to moderate kidney or liver impairment, but should be used with caution in severe impairment Drug Interactions GLP-1 medications can affect the absorption of oral medications due to delayed gastric emptying

The most important known patterns for the therapeutic effects of GIP agonism as well as antagonism in preventing obesity and in reducing body weight are summarized in Table 1 (49)